Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 11:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

NCT01087502
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
16
States / cities
Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833
View directory record Official record
Conditions
Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
Interventions
Nintedanib, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional

A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

NCT06309992
View directory record Official record
Conditions
Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Interventions
Survodutide, Placebo
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
33
States / cities
Fountain Valley, California • Gardena, California • Long Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Not yet recruiting Phase 3 Interventional

SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

NCT07855900
View directory record Official record
Conditions
Obesity
Interventions
Survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Riverview, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed No phase listed Observational

ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1

NCT02569528
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

NCT05182840
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 690517, Placebo to BI 690517, Empagliflozin, Placebo to empagliflozin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
41
States / cities
Mesa, Arizona • Phoenix, Arizona • Canyon Country, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional Results available

A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

NCT05670587
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Lakewood, Colorado • Reno, Nevada • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Different Doses of BI 1569912 in People With Depression

NCT06558344
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
35
States / cities
Bellflower, California • Long Beach, California • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Early Phase 1 Interventional Results available

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00870896
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
Tiotropium
Drug
Lead sponsor
ThomasTruncale
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease

NCT01072396
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Jasper, Alabama • Torrance, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

NCT05321082
View directory record Official record
Conditions
Lung Diseases, Interstitial
Interventions
BI 1015550, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

NCT01172821
View directory record Official record
Conditions
Asthma
Interventions
placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 14, 2026, 11:23 PM EDT
Completed No phase listed Observational

Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes

NCT04316780
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Retrospective observational study- no intervention to occur.
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
Not listed
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Iowa City, Iowa • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

NCT04876391
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab 1200 mg, Spesolimab 600 mg, Placebo matching 600 mg Spesolimab, Placebo matching 1200 mg Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 1 Interventional

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

NCT01577550
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Burbank, California • Miami, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

NCT04002310
View directory record Official record
Conditions
Macular Degeneration
Interventions
BI 754132
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 14, 2026, 11:23 PM EDT
Active, not recruiting Phase 2 Interventional

Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study

NCT03886246
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Auburn Hills, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 2 Interventional

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

NCT00148486
View directory record Official record
Conditions
Parkinson Disease
Interventions
NS 2330
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 80 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
47
States / cities
Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 14, 2026, 11:23 PM EDT
Terminated Phase 1 Interventional

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

NCT01485874
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Indianapolis, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 14, 2026, 11:23 PM EDT
Recruiting No phase listed Observational

Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People.

NCT00404989
View directory record Official record
Conditions
HIV Infections, Hepatitis B
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
12 Years to 60 Years · Female only
Enrollment
24,258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2099
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Not applicable Interventional

Use of Wii Home Computer in Patients With Chronic Obstructive Pulmonary Disease: Effects on Quality of Life

NCT01539421
View directory record Official record
Conditions
COPD
Interventions
Use of Home exercise computer program
Behavioral
Lead sponsor
Trinity Health Of New England
Other
Eligibility
40 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 14, 2026, 11:23 PM EDT
Completed Phase 4 Interventional Results available

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

NCT02845752
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Stiolto Respimat, Placebo Respimat
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
45 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 14, 2026, 11:23 PM EDT